Zydus Lifesciences Limited (BOM:532321)
1,120.00
+11.20 (1.01%)
At close: Aug 21, 2026
Zydus Lifesciences Revenue
Zydus Lifesciences had revenue of 80.17B INR in the quarter ending June 30, 2026, with 21.96% growth. This brings the company's revenue in the last twelve months to 285.92B, up 21.11% year-over-year. In the fiscal year ending March 31, 2026, Zydus Lifesciences had annual revenue of 271.48B with 16.81% growth.
Revenue (ttm)
285.92B
Revenue Growth
+21.11%
P/S Ratio
3.91
Revenue / Employee
9.54M
Employees
29,980
Market Cap
1.12T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 271.48B | 39.07B | 16.81% |
| Mar 31, 2025 | 232.42B | 36.94B | 18.90% |
| Mar 31, 2024 | 195.47B | 23.10B | 13.40% |
| Mar 31, 2023 | 172.37B | 21.28B | 14.08% |
| Mar 31, 2022 | 151.10B | 7.06B | 4.90% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Dr. Reddy's Laboratories | 331.19B |
| Lupin | 299.67B |
| Torrent Pharmaceuticals | 157.23B |
| Jubilant Pharmova | 86.08B |
| Abbott India | 70.04B |
| Granules India | 56.32B |
| J. B. Chemicals & Pharmaceuticals | 41.48B |
| GlaxoSmithKline Pharmaceuticals | 39.55B |
Zydus Lifesciences News
- 11 days ago - Mereo BioPharma Licenses Alvelestat Rights To Sentynl Therapeutics - Nasdaq
- 11 days ago - Zydus Life Q1 PAT falls 36% to Rs 940 crore as revenue rises 22% - The Times of India
- 11 days ago - Zydus Lifesciences Transcript: Q1 26/27 - Transcripts
- 11 days ago - Zydus Lifesciences Quarterly report: Q1 2027 - Filings
- 11 days ago - Zydus Lifesciences Slides: Q1 2027 - Filings
- 4 weeks ago - Zydus gets approval for Phase III trial of sickle cell disease drug - The Times of India
- 7 weeks ago - Zydus Lifesciences extends API business acquisition deadline to September 2026 - Business Upturn
- 2 months ago - Zydus Lifesciences invests USD 5 million in joint venture with Sunshine Healthcare - Business Upturn